VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies

Inclusion Criteria: Disease criteria: Patients with the following hematological malignancies: * Acute Myeloid Leukemia (AML) in complete remission (CR) * Acute Lymphoblastic Leukemia (ALL) in complete remission (CR) * Myelodysplastic Syndrome (MDS) requiring intensive chemotherapy * Non-Hodgkin lymphoma in complete or partial remission * Hodgkin lymphoma in complete or partial remission Age Criteria: \- 18 years up to 65 years. Organ Function and Performance Status Criteria: \- Performance status score: Karnofsky Score ≥60 Adequate major organ function defined as: * Left ventricular ejection fraction ≥40% * Pulmonary function test demonstrating DLCO ≥50% predicted and corrected for hemoglobin * Serum creatinine ≤ 2 mg/dL * Transaminases ≤ 3x ULN * Bilirubin ≤3x ULN except for in case of Gilbert's syndrome or ongoing hemolysis * Ability to understand and the willingness to sign a written informed consent document Donor availability: -Lack of suitable HLA matched related or unrelated donor available within 30 days or less if BMT is urgent in the opinion of the transplant physician. Exclusion Criteria: * Progressive, persistent disease or active malignancy * Greater than 10% blasts on bone marrow biopsy in patients with MDS * Chemotherapy naïve * History of myelofibrosis * Presence of Bone Marrow Fibrosis grade 2/3 * Presence of donor specific anti-HLA antibodies against available UCB units at A, B, C or DR loci, with a mean fluorescence intensity (MFI)\>1000 * History of prior allogeneic stem cell transplantation * Uncontrolled viral, bacterial or fungal infection * History of HIV infection * Presence of active CNS disease at the time of transplantation * Pregnant or breastfeeding female * Inability or unwillingness to use effective birth control.